ASND Shariah Compliance
Screening Methodology: AAOIFI
UNLOCK FOR FREE
Last Updated: March 05, 2026
Report Source: 2025 Annual Report
Ascendis Pharma A/S. Stock Analysis ASND
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Read More Ascendis Pharma A/S (ASND) Chart
Key Statistics of Ascendis Pharma A/S (ASND)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$226.13Volume
330.91KP/E Ratio (TTM)
-52 Week Range
Market Cap
13.68BAvg. Volume
740.89KDividend Yield
-Financial Metrics & Statements of Ascendis Pharma A/S (ASND)
Super Investors Invested in Ascendis Pharma A/S (ASND)
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
FAQ's for Ascendis Pharma A/S (ASND)
- According to Musaffa’s Shariah screening methodology, Ascendis Pharma A/S (ASND) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
Related Halal Stocks to Ascendis Pharma A/S (ASND)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.

